Section 1-1 of Japan's MSA-G — the Purpose clause — is short. It states that the guideline aims to "ensure the appropriate use of prescription drugs and contribute to the improvement of public health." But the surrounding context is specific: Japan's existing regulatory architecture for prescription drug promotion had two pillars — package insert obligations and the prohibition on false or exaggerated advertising under PMD Act Article 66 — and both were leaving identifiable gaps. This clause adds a third pillar, and identifies the three categories of conduct that the first two could not reach.
The goal stated in Section 1-1 — appropriate use and public health — is the same goal that drug labeling and advertising rules pursue. The difference is the instrument. The MSA-G acts directly on sales information activities, a domain the existing rules were not designed to regulate. Reading Section 1-1 carefully shows not just what the guideline aims to achieve, but what problem it was written to solve.
01The Limits of Existing Rules — Why a Third Pillar Was Needed
PMD Act Article 66 prohibits false or exaggerated advertising. "Advertising" under Japanese law requires three elements: identification of a specific product, inducement to purchase or use, and communication to the public. Information provision that fails to meet one of those elements may fall outside Article 66's reach entirely. A medical representative answering an unsolicited question from a physician, or handing over a journal article "as background reading," often cannot be characterized as advertising — and prosecuting it under Article 66 is difficult even where it probably should count.
The Fair Competition Code (Tekisei Kokoku Kijun) operates as a supplement to Article 66, and shares the same limitation: it presupposes an advertisement. Misleading-but-technically-accurate promotion often escapes it.
So what: The MSA-G is not an extension of pharmaceutical advertising law — it is a parallel instrument that applies to conduct outside the "advertising" definition. A company cannot use "this isn't an advertisement" as a defense to MSA-G compliance obligations.
So why: Leaving a loophole that allows unregulated influence over prescribing behavior — as long as the format is not "advertising" — was incompatible with the goal of ensuring appropriate use. A separate instrument was needed to close it.
02Category 1 — Verbal Explanations That Leave No Documentary Record
A medical representative speaking directly with a physician leaves no transcript, no recording, and no file that compliance officers can later review. Verbal descriptions of patient selection criteria, or verbal comparisons with competitor products, may encourage prescribing beyond the approved indication — and there is no way to confirm after the fact what was actually said.
The MSA-G addresses this by including oral explanations within the definition of "materials" (Section 1-2), and by requiring that information conveyed verbally be pre-approved through the same internal review process as printed materials. The objective is to bring verbal activity under company control, not to leave it to the discretion of individual representatives.
So what: "It was verbal, so there's no record, so no one can be held responsible" does not work as a compliance position under the MSA-G. Oral information provision is subject to the same company-level management as printed materials.
So why: In many clinical settings, what a representative says in person has more influence on prescribing decisions than printed materials. Leaving the highest-impact channel unregulated would have been inconsistent with the guideline's purpose.
03Category 2 — Information Provision That Falls Short of False Claims but Nudges Toward Inappropriate Use
"The trial demonstrated a statistically significant difference" is factually accurate. But if that statement is presented without context — without specifying the patient population studied, the primary endpoint used, or the nature of the comparator — a physician may reasonably conclude that the benefit applies to a broader population than the trial actually demonstrated. No false statement was made, but the impression created is misleading.
Materials that emphasize efficacy without adequate safety information, or disease awareness activities targeting the general public that serve in practice to promote a specific medicine, fall into this category. The MSA-G identifies this pattern — true but constructed to mislead — as one of the core problems it was created to address.
So what: "Everything we said was factually accurate" is not a sufficient compliance defense under the MSA-G. The question is whether the combination of what was said, what was omitted, and how it was framed could lead a reasonable physician toward inappropriate prescribing.
So why: Physicians cannot independently verify the full context behind every claim they encounter. A company holds information that prescribers do not have access to. The MSA-G requires that information asymmetry not be exploited to create misleading impressions through technically accurate statements.
04Category 3 — Research Papers and Other Content Where Company Involvement Is Not Apparent
A company that funds a clinical trial may eventually provide the resulting publication to physicians as "the latest evidence." If the company's role in funding the trial is not disclosed, the physician receives what appears to be an independent scientific finding. The practical effect on prescribing behavior may be indistinguishable from direct promotional advertising — but because the content takes the form of a peer-reviewed publication, the advertising rules may not apply.
The MSA-G covers this category: it requires transparency about company involvement in the research underlying materials provided to healthcare professionals, and requires that the selection of papers for distribution be fair and balanced rather than curated to support a predetermined conclusion.
So what: Distributing reprints of company-funded studies without disclosing the funding source, or providing review articles authored by company employees under an academic affiliation, are activities the MSA-G reaches. "This is scientific literature, not advertising" does not move the conduct outside the guideline's scope.
So why: Publications carry an implicit authority that promotional materials do not. A company that can influence prescribing behavior by supplying strategically selected peer-reviewed papers, while avoiding the obligations that attach to advertising, has a structural advantage that the MSA-G was designed to remove.
The Purpose clause in Section 1-1 establishes both a goal — appropriate use of prescription drugs and improvement of public health — and a diagnosis: that goal is being undermined by three categories of conduct that existing rules were not equipped to address. Understanding these three categories is the practical starting point for MSA-G compliance. For any given activity, the question is: does this fall within verbal-but-unrecorded promotion, misleading-but-accurate information provision, or opaque company-linked scientific content? If the answer to any of these is yes, the MSA-G framework applies regardless of whether the conduct meets the legal definition of "advertising."